Ixekizumab and ustekinumab in psoriasis: post-hoc comparison of onset and duration of treatment response

J Dermatolog Treat. 2022 Mar;33(2):1168-1170. doi: 10.1080/09546634.2020.1782317. Epub 2020 Jun 26.

Authors

Marc Radtke¹, Curdin Conrad², Christopher Schuster^{3

4}, Daniel Saure³, Can Mert⁵, Elisabeth Riedl^{3

4}, Antonio Costanzo⁶

Affiliations

¹ Dermatologikum Hamburg GmbH, Hamburg, Germany.
² Centre Hospital University Vaudois, Lausanne, Switzerland.
³ Eli Lilly and Company, Indianapolis, IN, USA.
⁴ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
⁵ HaaPacs GmbH, Schriesheim, Germany.
⁶ Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy.

PMID: 32530342
DOI: 10.1080/09546634.2020.1782317

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Duration of Therapy
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome
Ustekinumab* / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
ixekizumab
Ustekinumab